u/noor_hovland

Small correction: 2.4mg is the maintenance ceiling on the label, not the starting maintenance dose. The distinction matters for anyone reading this later.

STEP-1 ran 68 weeks and landed just under 15% mean body weight change on 2.4mg. It is an average of a wide distribution, not a target you have missed.

Tolerance to the gastric effect develops with continued exposure while the appetite effect largely persists. That single fact explains most of the "it settles but it still works" pattern the side-effect board reports.

Dosing intuitions from the GLP-1 boards do not transfer.

Agreed, and the combination arms are where the interesting numbers actually live.

Went looking for independent results on this and found a handful across the whole site. That is the honest state of the evidence.

GIP receptor biology is genuinely unsettled — there is a live argument about agonism versus antagonism at the receptor — and the clinical results are robust regardless, which is an uncomfortable and interesting position.

the first four weeks are a tolerance check, not a weight-loss phase

Yes — and the honest version is that most of the "it stopped working" posts turn out to be a normal fortnight of water weight.

Monotherapy arm or combination arm?

Glucose-dependent insulin secretion is why hypoglycaemia risk is low as monotherapy: the effect scales with glycaemia rather than acting unconditionally.

amylin and GLP-1 are not redundant pathways

keep the script and the receipt for private health claims

Correction to my own post above — I said 12.5mg and I have been on 12.5mg since the spring. Same argument, wrong number.

the appetite effect is blunter than sema, in a good way, most weeks

The incretin effect is the observation that oral glucose provokes a larger insulin response than intravenous glucose at matched glycaemia, and the difference is mediated by gut hormones. That is the foundation the whole class sits on.

private script pricing varies by pharmacy here too

Nothing containing this compound is approved as a standalone product, and research-use-only material is not approved for human use.

Added ApoB to the panel after a thread here. It told me something the standard lipid panel had been hiding.

stalling at 0.25mg is information, not a verdict

Push back: "gentler than sema" is a population statement.

Not sure about this bit. The GIP arm being real does not tell you that it is what caused your particular week.

Is there any independent purity data on this compound that you have seen?

confirmations are the only status that means anything

The distribution matters more than the mean. In the trial population the interquartile spread was wide enough that two honest people can have completely different runs on the same arm.

Yes. The discussion section is where the authors say what they actually think, and almost nobody here reads it.

A log is only interpretable if the conditions are consistent.

ahmed_abubakar is right about blanks. Silent gaps make the series lie.

Steady state after a dose change takes four to five half-lives, so the fair judgement point on a new step is about a month, not four days.

Cosigning on keeping the hash. It is the only receipt in existence and people screenshot their balance instead.

Push back: an unconfirmed transaction is not a missing payment. Wait for confirmations before escalating.

Correction: that address format is not the chain you named. Worth checking before anybody follows this.

confirmations are the only status that means anything

dual agonist, so the GIP arm is doing something the sema threads will not tell you about

nothing containing this is approved as a standalone product

Correcting myself upthread: I gave the 49-week figure and the paper reports 92 weeks.

Yes. Anyone reading this board should hold their conclusions loosely until phase 3 reports.

That study was in a rodent model. Worth stating, since the thread has been reading it as human data.

STEP-1 ran 68 weeks and landed just under 15% mean body weight change on 2.4mg. It is an average of a wide distribution, not a target you have missed.

Did you send a test amount first?

protein first, then everything else gets easier

Personal importation provisions exist, are narrow, and carry conditions. Any summary of them here should be checked against the current official wording rather than a forum post.